PDCD1 and cancer: The interplay of SHP2 with PD-1, including feedback mechanisms, and its broader impact on TCR signaling and immune regulation continue to be active areas of research, influencing our understanding of T-cell responses, especially in the context of cancer immunotherapy [3,39,41].